52
Participants
Start Date
September 12, 2013
Primary Completion Date
December 21, 2017
Study Completion Date
December 21, 2017
Intranasal oxytocin
Oxytocin can be given intravenously (with a needle) or intranasally (a spray into the nose). The intravenous form of drug is approved by Health Canada for use in pregnancy. The intranasal formulation is not currently approved for use by Health Canada, but is used in Europe to induce labour in pregnant women or aid lactation (breastfeeding). Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3.
Saline Nasal Mist
Participants will be randomized to receive placebo on either study visit 2 or 3.
Parkwood Hospital, London
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
OTHER